Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst on December 12. Analyst Michael Ulz from Morgan Stanley maintained a Hold rating on the stock and has a $495.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Ulz has given his Hold rating due to a combination of factors related to Alnylam Pharmaceuticals’ recent performance and projections. The analysis of monthly script data for Amvuttra suggests that the sales for the fourth quarter of 2025 are slightly below the consensus estimate, although they align with the company’s guidance. Specifically, the estimated worldwide sales for Amvuttra are around $820 million, which is less than the consensus of $857 million.
Additionally, when considering the total TTR franchise sales, including Onpattro, the worldwide sales are projected to be approximately $859 million, again falling short of the consensus expectation of $896 million. This shortfall in sales projections, despite being within the company’s guidance range, contributes to the Hold rating. The report also notes that Alnylam is expected to release preliminary fourth-quarter and full-year 2025 sales figures in early January, with further guidance anticipated during the fourth-quarter earnings release.
In another report released on December 3, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $477.00 price target.
ALNY’s price has also changed moderately for the past six months – from $304.670 to $397.550, which is a 30.49% increase.